Affibody Medical Investor Relations
Categories:
Navigation:
Non-Regulatory
August 27, 2021
Interim Report – January to June 2021
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod®,...
Read more
August 22, 2014
Interim Report – January to June 2014
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its...
May 20, 2014
Interim Report – January to March 2014
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...
April 28, 2014
First Patient Included in PET Imaging Study of HER2 Expression in Breast Cancer
Solna, Sweden, April 28, 2014. Affibody is pleased to announce that the first patient has been enrolled in a clinical study to evaluate ABY-025 for PET imaging of HER2...
April 8, 2014
Kallelse till årsstämma
Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma torsdagen den 8 maj 2014 kl 13.30 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.
February 20, 2014
Year End Report 2013
November 19, 2013
Interim Report – January to September 2013
November 5, 2013
Sobi announces phase I Complement Inhibitor program
Swedish Orphan Biovitrum AB (publ) (Sobi) announced its intention to bring a novel investigational biopharmaceutical drug candidate, SOBI002, into a phase I trial today at the company’s Capital Markets...
October 1, 2013
EU Funded Effort to Develop New Stroke Therapies
Solna, Sweden, October 1, 2013. The COUNTERSTROKE consortium led by researchers at Karolinska Institutet today initiates a six million Euro EU funded collaboration to develop novel therapeutics to treat...
